Brickell Biotech to Participate at William Blair Biotech Focus Conference 2022
BOULDER, Colo., July 06, 2022 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. (“Brickell” or the “Company”) (Nasdaq: BBI), a clinical-stage pharmaceutical...
Staff
Inspire Medical Systems, Inc. Announces FDA Approval of Expanded, Full-Body MRI Compatibility with Inspire Therapy
MINNEAPOLIS, July 06, 2022 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE: INSP) (Inspire), a medical technology company focused on...
Ring Therapeutics Publishes the First Human Anellovirus Structure with Key Insights on Its Assembly, Function and Immune Evasion Properties
– New data describe the first structure of anellovirus particles, including a novel jelly roll domain architecture – – Structural...
Immutep Granted Japanese Patent for IMP761, A First-In-Class Immunosuppressive Antibody Targeting Lag-3
SYDNEY, AUSTRALIA, July 06, 2022 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology...
Eyenovia Strategic Partner Arctic Vision Enrolls First Patient in Phase III Clinical Trial of ARVN003 (MicroLine) for Presbyopia in China
Arctic Vision also licensed and is developing Eyenovia’s programs for pediatric progressive myopia (MicroPine) and pharmacologic mydriasis (MydCombi™) in Greater...
Catalyst Biosciences Comments on Favorable Delaware Court of Chancery Ruling
Court Denies JDS1’s Motion for Expedited Proceedings Board Reiterates Commitment to Distributing Cash to Stockholders Once Potential Liability and Expenses...
Cornerstone Pharmaceuticals Strengthens Scientific Advisory Board with the Appointment of Distinguished Scholar Jason Locasale, Ph.D.
CRANBURY, N.J., July 06, 2022 (GLOBE NEWSWIRE) -- Cornerstone Pharmaceuticals, Inc. (“Cornerstone” or the “Company”), a company focused on rare...
Extendicare Announces Timing of 2022 Second Quarter Results and Conference Call
MARKHAM, Ontario, July 06, 2022 (GLOBE NEWSWIRE) -- Extendicare Inc. (“Extendicare” or the “Company”) (TSX: EXE) announced today that it...
HTG Releases Second Whitepaper for its Transcriptome-Informed Approach to Drug Discovery
TUCSON, Ariz., July 06, 2022 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a life science company advancing...
Selecta Biosciences to Participate at the Guggenheim I&I Spotlight Series – Treg-based Therapies Conference
WATERTOWN, Mass., July 06, 2022 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated...
BetterLife Secures Additional Mitacs Funding in Collaboration with Carleton University Research Team for BETR-001 Preclinical Depression Studies
VANCOUVER, British Columbia, July 06, 2022 (GLOBE NEWSWIRE) -- BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF...
Applied Molecular Transport Announces Top-line Phase 2 Results from MARKET Combination Trial of Oral AMT-101 in Patients with Moderate-to-Severe Ulcerative Colitis
– Similar clinical remission rates observed of 31.8% (7/22) in patients receiving combination (AMT-101 and adalimumab) versus 33.3% (9/27) in...
Caladrius Biosciences and Cend Therapeutics Announce Publication of Pancreatic Cancer Trial Data in The Lancet Gastroenterology and Hepatology
Peer-reviewed study data suggest CEND-1, in combination with gemcitabine and nab-paclitaxel, demonstrates favorable safety and tolerability along with encouraging efficacyBASKING...
Oncocyte Presents DetermaIO™ Data in Podium Presentation at ESMO World Congress on Gastrointestinal Cancer 2022
Researchers conducted exploratory analysis to find an optimized IO score after validation of original established endpoint was presented at the...
Coherus and Junshi Biosciences Announce FDA Acceptance of Resubmission of BLA for Toripalimab for the Treatment of Nasopharyngeal Carcinoma
- FDA has set a target action date of December 23, 2022 for the toripalimab BLA - - Toripalimab will...
Junshi Biosciences and Coherus Announce FDA Acceptance of Resubmission of BLA for Toripalimab for the Treatment of Nasopharyngeal Carcinoma
- FDA has set a target action date of December 23, 2022 for the toripalimab BLA - - Toripalimab will...
Alignment Healthcare to Announce Second Quarter 2022 Financial Results and Host Conference Call Thursday, Aug. 4, 2022
ORANGE, Calif., July 06, 2022 (GLOBE NEWSWIRE) -- Alignment Healthcare, Inc. (“Alignment Healthcare” or the “Company”) (Nasdaq: ALHC), a tech-enabled...
Protega Pharmaceuticals™ LLC Announces Commercialization of RoxyBond™ (oxycodone hydrochloride) Tablets CII in the U.S.
RoxyBond is the first and only immediate-release opioid medication with FDA-approved labeling describing abuse-deterrent properties.1 PRINCETON, N.J., July 06, 2022...
Femasys Inc. Announces Existing Board Member Charles Larsen as Chairperson of the Board
Mr. Larsen brings over 40 years of medical device industry experience and skills strongly aligned with the Company’s strategy to...
NextCure Announces Development of a Highly Specific Immunohistochemical Diagnostic for Siglec-15-positive Tumors as reported in Laboratory Investigation
BELTSVILLE, Md., July 06, 2022 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel,...